Altria Group, Inc. released its Q3 and nine-month earnings report for 2024 on its official website. The report shows that Q3 net revenue declined by 0.4% to $6.3 billion, while net revenue excluding excise taxes increased by 1.3% to $5.3 billion.
For the first nine months, net revenue dropped by 2.5% to $18 billion, and net revenue excluding excise taxes decreased by 0.9% to $15.3 billion. The revenue decline was primarily attributed to decreased net revenue in the smokeable products segment.
The report indicates that Q3 NJOY consumables shipments rose by 15.6% year-on-year, reaching 10.4 million units. NJOY device shipments doubled, up 100% to 1.1 million units. NJOY’s retail share of consumable products in the U.S. multi-channel and convenience store segments increased by 2.8% YoY, reaching 6.2%.
For the first nine months, NJOY consumable shipments totaled 33.8 million units, while device shipments reached 3.9 million units. NJOY’s retail share for consumables in the U.S. multi-channel and convenience store segments stood at 5.3%.
In Q3, nicotine pouches accounted for 43.9% of the U.S. oral tobacco category, an increase of 11.4% YoY, with on! nicotine pouches holding a 20.3% share within the nicotine pouch segment.
Over the first nine months, the nicotine pouch segment’s share of the U.S. oral tobacco market grew to 41.9%, up 12.4% YoY, while on! held a 19.1% share, marking a 3.8% decrease from the previous year.
Altria CEO Billy Gifford commented: "Altria achieved outstanding performance in the third quarter, with resilient Marlboro-driven revenue growth in the combustible products segment, and our MST brand continued to drive profitability in the oral tobacco segment while the on! brand maintained its momentum. We continue to reward shareholders through dividend growth and share repurchases while investing to pursue our vision."
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
